Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
06/27/2023 | ARS Pharmaceuticals, Inc. | SBTX | Grant | Stock Option (right to buy) | 40k | $6.50 | $260k | | 06/27/2023 |
01/03/2023 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Grant | Stock Option (Right to buy) | 10k | $0.00 | $0 | | 01/03/2023 |
09/16/2022 | Edgewise Therapeutics, Inc. | | Purchase | Common Stock | 484.5k | $10.32 | $5M | See Footnotes | 09/16/2022 |
08/11/2022 | Corvus Pharmaceuticals, Inc. | CRVS | Grant | Stock Option (Right to Buy) | 15k | $0.97 | $14.5k | | 08/11/2022 |
06/24/2022 | Edgewise Therapeutics, Inc. | | Grant | Stock Option (Right to Buy) | 42.1k | $8.53 | $359k | | 06/24/2022 |
06/17/2022 | Decibel Therapeutics, Inc. | DBTX | Grant | Stock Option (right to buy) | 10k | $2.30 | $23k | | 06/17/2022 |
06/15/2022 | Corvus Pharmaceuticals, Inc. | CRVS | Grant | Stock Option (Right to Buy) | 15k | $0.99 | $14.8k | | 06/15/2022 |
06/14/2022 | Janux Therapeutics, Inc. | | Grant | Stock Option (right to buy) | 12.5k | $10.73 | $134.1k | | 06/14/2022 |
06/10/2022 | ARS Pharmaceuticals, Inc. | SBTX | Grant | Stock Option (right to buy) | 18k | $4.18 | $75.2k | | 06/10/2022 |
06/02/2022 | PMV Pharmaceuticals, Inc. | PMVP | Grant | Stock option (right to buy) | 16.3k | $32.29 | $527.4k | | 06/02/2021 |
05/18/2022 | Edgewise Therapeutics, Inc. | | Purchase | Common Stock | 138k | $7.21 | $995k | See Footnotes | 05/18/2022 |
01/03/2022 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Grant | Stock Option (Right to buy) | 10k | $0.00 | $0 | | 01/03/2022 |
12/29/2021 | Janux Therapeutics, Inc. | | Sale | Common Stock | 36.7k | $20.30 | $745k | See Footnotes | 12/29/2021 |
12/29/2021 | Janux Therapeutics, Inc. | | Sale | Common Stock | 3.7k | $20.30 | $75.1k | See Footnotes | 12/29/2021 |
12/21/2021 | Janux Therapeutics, Inc. | | Sale | Common Stock | 108.3k | $19.00 | $2.1M | See Footnotes | 12/21/2021 |
12/21/2021 | Janux Therapeutics, Inc. | | Sale | Common Stock | 11.1k | $19.00 | $210.9k | See Footnotes | 12/21/2021 |
12/16/2021 | Janux Therapeutics, Inc. | | Sale | Common Stock | 36.5k | $19.07 | $696.1k | See Footnotes | 12/16/2021 |
12/16/2021 | Janux Therapeutics, Inc. | | Sale | Common Stock | 356.8k | $19.07 | $6.8M | See Footnotes | 12/16/2021 |
09/20/2021 | Corvus Pharmaceuticals, Inc. | CRVS | Sale | Common Stock, $0.0001 par value | 1.1M | $6.09 | $6.8M | See Footnotes | 09/20/2021 |
09/17/2021 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Purchase | Common Stock | 585.1k | $9.40 | $5.5M | See Footnotes | 09/17/2021 |
09/17/2021 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Purchase | Common Stock | 425.5k | $9.40 | $4M | See Footnotes | 09/17/2021 |
09/09/2021 | Corvus Pharmaceuticals, Inc. | CRVS | Grant | Stock Option (Right to Buy) | 15k | $2.60 | $39k | | 09/09/2021 |
06/15/2021 | Janux Therapeutics, Inc. | | Conversion | Common Stock | 1.3M | $0.00 | $0 | See footnotes | 06/15/2021 |
06/15/2021 | Janux Therapeutics, Inc. | | Conversion | Common Stock | 823.7k | $0.00 | $0 | See footnotes | 06/15/2021 |
06/15/2021 | Janux Therapeutics, Inc. | | Purchase | Common Stock | 588.2k | $17.00 | $10M | See footnotes | 06/15/2021 |
06/15/2021 | Janux Therapeutics, Inc. | | Conversion | Common Stock | 164.7k | $0.00 | $0 | See footnotes | 06/15/2021 |
06/15/2021 | Janux Therapeutics, Inc. | | Purchase | Common Stock | 117.6k | $17.00 | $2M | See footnotes | 06/15/2021 |
06/15/2021 | Janux Therapeutics, Inc. | | Conversion | Series A Convertible Preferred Stock | 1.1M | $0.00 | $0 | See footnotes | 06/15/2021 |
06/15/2021 | Janux Therapeutics, Inc. | | Conversion | Series B Convertible Preferred Stock | 643k | $0.00 | $0 | See footnotes | 06/15/2021 |
06/15/2021 | Janux Therapeutics, Inc. | | Conversion | Series B Convertible Preferred Stock | 128.6k | $0.00 | $0 | See footnotes | 06/15/2021 |
06/15/2021 | Corvus Pharmaceuticals, Inc. | CRVS | Grant | Stock Option (Right to Buy) | 15k | $2.74 | $41.1k | | 06/15/2021 |
06/10/2021 | Janux Therapeutics, Inc. | | Grant | Stock Option (right to buy) | 30k | $17.00 | $510k | | 06/10/2021 |
06/04/2021 | ARS Pharmaceuticals, Inc. | SBTX | Grant | Stock Option (right to buy) | 15k | $28.83 | $432.4k | | 06/04/2021 |
03/30/2021 | Edgewise Therapeutics, Inc. | | Conversion | Series B-1 Preferred Stock | 1.6M | $0.00 | $0 | See Footnotes | 03/30/2021 |
03/30/2021 | Edgewise Therapeutics, Inc. | | Conversion | Series A Preferred Stock | 8.2M | $0.00 | $0 | See Footnotes | 03/30/2021 |
|